Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBruising at the injection site is a recognised, common side effect of Mounjaro (tirzepatide). It happens when the needle nicks a small blood vessel under the skin, causing a localised bruise that usually fades within a few days. It is not a sign the medicine is harmful or that something has gone wrong with your dose. That said, bruising that spreads, lingers, or is accompanied by other symptoms is worth discussing with your prescriber. Mounjaro is a prescription-only medicine, and every person who starts or continues treatment through nume has their suitability and any side effects assessed by a GPhC-registered Independent Prescriber as part of the consultation process.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro is given as a once-weekly subcutaneous injection, meaning the needle enters the fatty layer just beneath the skin rather than a vein or muscle. That layer is crossed by many tiny capillaries. When the needle tip passes close to one, a small amount of blood can leak into the surrounding tissue before clotting. The result is the familiar blue-purple mark that most people have seen after a blood test or a bump.
The size of the bruise depends on factors outside your control: the exact depth of your subcutaneous layer, whether you happen to catch a capillary that day, and whether you are taking any medicines that affect clotting (such as aspirin or anticoagulants). Pressing gently on the site with a clean finger for ten to fifteen seconds after removing the pen can reduce the likelihood of a bruise forming. The Mounjaro overview page covers how the KwikPen works and general injection guidance.
A question our prescribers hear most weeks is whether bruising means the injection was given incorrectly. Usually it does not. Even technique that is entirely by the book occasionally produces a bruise simply because you cannot see the capillaries before inserting the needle.
For the vast majority of people, a small injection-site bruise is nothing more than a cosmetic nuisance. It is listed as a common local reaction in Mounjaro's prescribing information, and the NHS patient guide on tirzepatide confirms injection-site reactions of this kind are expected.
Where bruising deserves more attention is when it moves beyond the ordinary pattern. A bruise that keeps growing after the first day, extends well beyond the injection site, feels hot or hard, or is accompanied by a raised temperature could indicate a local infection or haematoma rather than simple capillary leakage. Bruising that appears consistently across multiple sites, or unexpected bruising elsewhere on your body while on treatment, should be raised with your prescriber. People taking blood-thinning medicines are at greater risk of larger bruises and should let their prescriber know before starting treatment. You can read about the broader range of Mounjaro side effects to put injection-site reactions in context alongside GI symptoms and other commonly reported effects.
Antibody reactions to tirzepatide are rare but can present with skin changes. If you notice unusual skin responses beyond a standard bruise, the page on anti-tirzepatide antibody reactions explains what is currently known.
Most bruises need nothing more than time. Seek same-day medical advice if you notice any of the following: a bruise that is expanding rather than stabilising, significant swelling or hardness around the site, redness spreading outward from the injection point, a fever, or any bruising accompanied by severe or unusual pain. These could point to a haematoma, skin infection, or another reaction that needs assessment in person.
Beyond injection-site issues, be aware of signs that require urgent attention during Mounjaro treatment more generally. Severe, persistent stomach pain that reaches into your back, with or without vomiting, can be a symptom of acute pancreatitis; the MHRA highlighted this risk in a Drug Safety Update in January 2026 and advises seeking urgent medical help. Symptoms of a serious allergic reaction, including swelling of the face or throat and difficulty breathing, also need emergency care.
If you experience a side effect you believe may be linked to Mounjaro, you can report it directly to the MHRA at yellowcard.mhra.gov.uk. The Yellow Card scheme exists for exactly this purpose and helps regulators monitor medicine safety in real-world use. You can also contact the nume team through our support page, and a prescriber will review your concern.
A few straightforward habits make a measurable difference. Rotate your injection site every week, cycling between the abdomen, front of the thigh, and upper arm rather than returning to the same spot. Avoid skin that is already bruised, broken, or scarred. Let the pen come to room temperature before injecting, as cold medicine can cause more tissue irritation. Do not rub the site after removing the pen; gentle pressure is enough.
If you are consistently getting large bruises despite good technique, tell your prescriber at your next review. They may want to check whether any other medicine you are taking is a contributing factor. The full Mounjaro side effects page covers injection-site and systemic reactions together, and the pages on diarrhoea and burping address the GI reactions that tend to concern people more in the early weeks of treatment.
If you are considering starting Mounjaro and want to discuss how side effects are managed, check your eligibility and our prescribers will go through your individual circumstances during the free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.